IMMUNOPROPHYLAXIS OF SEVERE RESPIRATORY-SYNCYTIAL VIRAL INFECTION IN CHILDREN WITH BRONCHOPULMONARY DYSPLASIA: RESULTS OF 4 EPIDEMIC SEASONS

IMMUNOPROPHYLAXIS OF SEVERE RESPIRATORY-SYNCYTIAL VIRAL INFECTION IN CHILDREN WITH BRONCHOPULMONARY DYSPLASIA: RESULTS OF 4 EPIDEMIC SEASONS

Children with bronchopulmonary dysplasia belong to the risk group of severe respiratory-syncytial viral infection (RSV). World experience and authors' own clinical data show that seasonal immunoprophylaxis of RSV infection's severe course by palivizumab in these patients allows reducing fr...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	A. A. Baranov, I. V. Davydova, T. V. Turti, L. S. Namazova-Baranova, V. V. Altunin, E. P. Zimina, E. V. Pavlyukova
Μορφή:	Άρθρο
Γλώσσα:	Russian
Έκδοση:	Union of pediatricians of Russia 2012-12-01
Σειρά:	Педиатрическая фармакология
Θέματα:	respiratory-syncytial virus bronchopulmonary dysplasia acute respiratory viral infection respiratory function palivizumab
Διαθέσιμο Online:	https://www.pedpharma.ru/jour/article/view/268

Παρόμοια τεκμήρια

Immunoprophylaxis of Respiratory Syncytial Virus Infection in Children
ανά: A. A. Baranov, κ.ά.
Έκδοση: (2015-12-01)

PREVENTIVE STRATEGIES IN THE STAGES OF FORMATION AND COURSE OF BRONCHOPULMONARY DYSPLASIA
ανά: I. V. Davydova, κ.ά.
Έκδοση: (2014-03-01)

MUCOLYTICS IN BRONCHOPULMONARY DYSPLASIA THERAPY
ανά: I. V. Davydova, κ.ά.
Έκδοση: (2012-10-01)

Patient equity and respiratory syncytial virus Immunoprophylaxis
ανά: H. Cody Meissner
Έκδοση: (2019-01-01)

Respiratory-syncytial virus immunoprophylaxis on asthma symptoms development in prematurity with bronchopulmonary dysplasia
ανά: Li-Ching Fang, MD, κ.ά.
Έκδοση: (2023-11-01)

Respiratory syncytial virus hospitalizations in infants of 28 weeks gestational age and less in the palivizumab era
ανά: Bernhard Resch, κ.ά.
Έκδοση: (2017-04-01)

Respiratory Syncytial Virus Lower Respiratory Tract Infections in Premature Infants and Infants with Bronchopulmonary Dysplasia
ανά: D. Yu. Ovsyannikov, κ.ά.
Έκδοση: (2015-10-01)

Cost-utility analysis of palivizumab for preventing respiratory syncytial virus in preterm neonates and infants in Colombia
ανά: Jaime E. Ordóñez, κ.ά.
Έκδοση: (2024-04-01)

Incidence of respiratory syncytial virus infection in children with congenital heart disease undergoing immunoprophylaxis with palivizumab in Pará state, north region of Brazil
ανά: Roseane Porfírio de Souza, κ.ά.
Έκδοση: (2019-08-01)

Respiratory Morbidity in Prematurely Born Children Receiving Palivizumab Prophylaxis of Respiratory Syncytial Virus Disease
ανά: Milena Bjelica, κ.ά.
Έκδοση: (2024-04-01)

Immunoprophylaxis of respiratory syncytial virus: global experience
ανά: Simoes Eric AF
Έκδοση: (2002-06-01)

Resurgence of Respiratory Syncytial Virus in Children: An Out-of-Season Epidemic in Portugal
ανά: Ana Rita Torres, κ.ά.
Έκδοση: (2023-01-01)

Modern Approaches in management of Children with Acute Bronchiolitis
ανά: Alexander A. Baranov, κ.ά.
Έκδοση: (2020-02-01)

FUNCTIONAL ASSESSMENT OF RESPIRATORY DISORDERS IN CHILDREN WITH BRONCHOPULMONARY DYSPLASIA DURING FOLLOW-UP
ανά: I. V. Davydova, κ.ά.
Έκδοση: (2014-11-01)

Adherence to Palivizumab for Respiratory Syncytial Virus Prophylaxis in Romanian Infants
ανά: Andreea Calomfirescu-Avramescu, κ.ά.
Έκδοση: (2025-02-01)

Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation
ανά: D Wang, κ.ά.
Έκδοση: (2008-12-01)

Effectiveness of palivizumab immunoprophylaxis to prevent respiratory syncytial virus hospitalizations in healthy full-term <6-month-old infants from the circumpolar region of Nunavik, Quebec, Canada
ανά: Rodica Gilca, κ.ά.
Έκδοση: (2020-12-01)

Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection
ανά: Bernhard Resch
Έκδοση: (2017-09-01)

A practical guidance on the prevention and treatment of childhood respiratory syncytial virus infection in Kurdistan
ανά: Azad A. Haleem, κ.ά.
Έκδοση: (2025-03-01)

Bronchopulmonary Dysplasia: An Overview
ανά: Gisondo CM, κ.ά.
Έκδοση: (2020-09-01)

Aerosol Delivery of Palivizumab in a Neonatal Lamb Model of Respiratory Syncytial Virus Infection
ανά: Hasindu S. Edirisinghe, κ.ά.
Έκδοση: (2023-11-01)

Prevention of respiratory syncytial virus infection in children. Recommendations of the Polish Society of Paediatrics and the National Paediatric Consultant
ανά: Teresa Jackowska, κ.ά.
Έκδοση: (2024-12-01)

Treatment and prophylaxis of moderate and severe bronchopulmonary dysplasia in premature neonates
ανά: A.V. Bolonska, κ.ά.
Έκδοση: (2021-09-01)

Changes in the patterns of respiratory support and incidence of bronchopulmonary dysplasia; a single center experience
ανά: Saleh S. Algarni, κ.ά.
Έκδοση: (2023-07-01)

Temporal-spatial analysis of hospitalizations for bronchiolitis in Brazil: prediction of epidemic regions and periods for immunization against the Respiratory Syncytial Virus
ανά: Edilenia Queiroz Pereira, κ.ά.
Έκδοση: (2023-03-01)

IMMUNOPTOPHYLAXIS OF THE RESPIRATORY SYNCYTIAL VIRAL INFECTION IN CHILDREN UNDER RISK OF HEAVY COURSE OF THE DISEASE: PRELIMINARY RESULTS OF IMPLEMENTING THE MOSCOW PROGRAM
ανά: A. A. Korsunskiy, κ.ά.
Έκδοση: (2012-06-01)

Bronchopulmonary dysplasia: clinical aspects and preventive and therapeutic strategies
ανά: Nicola Principi, κ.ά.
Έκδοση: (2018-02-01)

Respiratory support strategies in the management of severe, longstanding bronchopulmonary dysplasia
ανά: J. Wells Logan, κ.ά.
Έκδοση: (2022-11-01)

Respiratory syncytial virus seasonality in Brazil: implications for the immunisation policy for at-risk populations
ανά: André Ricardo Ribas Freitas, κ.ά.
Έκδοση: (2016-01-01)

Respiratory syncytial virus under 2 years of age: hospitalization trends and risk factors for severe disease â preliminary data from the Portuguese sentinel network
ανά: Ana R. Torres, κ.ά.
Έκδοση: (2024-01-01)

One‐year observational study of palivizumab prophylaxis on infants at risk for respiratory syncytial virus infection in Latin America
ανά: Leandro Martin Castillo, κ.ά.
Έκδοση: (2017-09-01)

Detection of the Onset of the Epidemic Period of Respiratory Syncytial Virus Infection in Japan
ανά: Hidetomi Yamagami, κ.ά.
Έκδοση: (2019-03-01)

A CLINICAL AND ECONOMICAL ANALYSIS OF THE RESULTS PRODUCED BY THE PROGRAM OF RSV-INFECTION PROPHYLAXIS DURING THE EPIDEMIOLOGICAL SEASON OF 2012/2013 IN MOSCOW
ανά: V. I. Ignat'eva, κ.ά.
Έκδοση: (2013-11-01)

Prevention and treatment of respiratory syncytial virus bronchiolitis and postbronchiolitic wheezing
ανά: Kimpen Jan LL
Έκδοση: (2002-06-01)

Respiratory syncytial virus outbreak in neonatal intensive care unit: Impact of infection control measures plus palivizumab use
ανά: Silva Camila de A, κ.ά.
Έκδοση: (2012-05-01)

Cost-effectiveness of nirsevimab and palivizumab for respiratory syncytial virus prophylaxis in preterm infants 29–34 6/7 weeks' gestation in the United States
ανά: Tianzhou Yu, κ.ά.
Έκδοση: (2024-03-01)

Respiratory syncytial virus immunization patterns in Germany, 2015–2020
ανά: Moritz Wick, κ.ά.
Έκδοση: (2024-12-01)

Palivizumab e virus respiratorio sinciziale: una panoramica
ανά: Paolo Manzoni
Έκδοση: (2011-07-01)

The impact of the recent AAP changes in palivizumab authorization on RSV-induced bronchiolitis severity and incidence
ανά: Antonino Capizzi, κ.ά.
Έκδοση: (2017-08-01)

Bronchiolitis - diagnostic and therapeutic difficulties in pediatric patients
ανά: Iwona Kowalska, κ.ά.
Έκδοση: (2020-03-01)